AngioDynamics

ANGO · NASDAQ

$11.81+$0.42 (+3.69%)TodayMarket closed ·
Prev close $11.39

About ANGO

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The company is headquartered in Latham, New York and currently employs 675 full-time employees. The company went IPO on 2004-05-27. The firm is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. The company designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters.

Employees
675
Headquarters
Latham, New York
Listed
May 27, 2004
Sector
Health Care
Industry
Health Care Equipment & Supplies

ANGO key statistics

Market cap
496.66M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.02M
Volume
1.14M
Open price
$11.46
High today
$11.96
Low today
$11.46
52 Week high
$16.29
52 Week low
$9.39

AngioDynamics (ANGO) at a glance

AngioDynamics (ANGO) last traded at $11.81, with a market cap of 496.66M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.46 and $11.96. The current price is 3.1% above the day's low and 1.3% below its high.

Volume so far is 1.14M shares, in line with the average of 1.02M shares a day.

Over the past year AngioDynamics has ranged from $9.39 to $16.29, and now sits 35% of the way up that range.

AngioDynamics met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q1 FY27 it reported -$0.04 per share against an estimate of -$0.1156.

The average analyst price target is $20.40, 72.7% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $20.40
Low
$17.17
Now
$11.81
High
$25.20

ANGO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 73.3% on average.

  1. Q2 FY25: reported -$0.04 per share against an estimate of -$0.1122
  2. Q3 FY25: reported $0.03 per share against an estimate of -$0.1326
  3. Q4 FY25: reported -$0.03 per share against an estimate of -$0.1224
  4. Q1 FY26: reported -$0.10 per share against an estimate of -$0.1199
  5. Q2 FY26: reported $0.00 per share against an estimate of -$0.102
  6. Q3 FY26: reported $0.02 per share against an estimate of -$0.1122
  7. Q4 FY26: reported -$0.07 per share against an estimate of -$0.0918
  8. Q1 FY27: reported -$0.04 per share against an estimate of -$0.1156

ANGO news

  • Press releaseBusiness Wire

    AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

  • Vandana Singh

    AngioDynamics Stock Is Falling Thursday: What's Going On?

  • Avi Kapoor

    Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings

  • AngioDynamics Q1 2027 Earnings Call: Complete Transcript

  • Press releaseBusiness Wire

    AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

  • Press releaseBusiness Wire

    AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

  • Press releaseBusiness Wire

    AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

  • Press releaseBusiness Wire

    AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

Similar companies

Companies in the same industry as AngioDynamics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.